Akebia Therapeutics, Inc. (AKBA)

NASDAQ: AKBA · Real-Time Price · USD

1.250

+0.030 (2.46%)

At close: Mar 4, 2026, 4:00 PM EST

1.258

+0.008 (0.66%)

After-hours: Mar 4, 2026, 4:48 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Developing and Commercializing Innovative Therapeutics	236.20M	160.18M	194.62M	292.48M	211.65M
Developing and Commercializing Innovative Therapeutics Growth	47.46%	-17.70%	-33.46%	38.19%	-28.17%
Total	236.20M	160.18M	194.62M	292.48M	211.65M
Total Growth	47.46%	-17.70%	-33.46%	38.19%	-28.17%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	236.20M	160.18M	194.62M	292.48M	211.65M
United States Growth	47.46%	-17.70%	-33.46%	38.19%	-28.17%
Total	236.20M	160.18M	194.62M	292.48M	211.65M
Total Growth	47.46%	-17.70%	-33.46%	38.19%	-28.17%

Source: S&P Global Market Intelligence.